Does ScreenMyGene recommend genetic testing before reversible causes are ruled out?

No. Structural- and reversible-cause safety gates are applied first, so a hereditary neuropathy or epilepsy panel is only surfaced when the documented workup supports a hereditary cause being clinically appropriate to pursue.

What neurological conditions does this cover?

Hereditary neuropathy, epilepsy, and related presentations, evaluated with Tier-1 gene-disease validity and safety gates appropriate to each presentation.

Why does a reversible-cause check matter for a genetic test recommendation?

Genetic testing is not the first move in most neuropathy workups. Common reversible causes are typically evaluated first, since skipping that step risks a genetic order for a presentation that had a non-genetic explanation.

Neurology

The most common way a hereditary neuropathy workup goes wrong isn't a missed gene.

It's an unruled-out B12 deficiency. Or an undiagnosed diabetic neuropathy. Or a medication effect nobody connected to the presenting symptoms. Hereditary causes account for a real and often underdiagnosed share of neuropathy and epilepsy cases — but they're not supposed to be the first hypothesis tested. They're supposed to be the one you reach after the reversible and structural causes have been checked and ruled out.

The hereditary pathway is the destination, not the starting point. The case advances only as each gate clears.

Safety gates before genetic gates

ScreenMyGene applies structural- and reversible-cause safety gates before a hereditary neuropathy or epilepsy panel is surfaced. That's not a limitation bolted on for compliance — it reflects how the workup is actually supposed to sequence. A genetic recommendation that skips this step isn't faster, it's just wrong more often, and it puts a specialist-grade panel behind a documentation gap a generalist workflow would have caught.

How it works for neurology specifically

1. Presentation and workup extraction — Documented symptoms, exam findings, and any completed workup are pulled from the chart.

2. Safety gate evaluation — Structural and reversible causes relevant to the presentation are checked against what's documented before a hereditary pathway is considered.

3. Tier-1 evaluator matching — Once safety gates clear, the presentation is matched against Tier-1 gene-disease evaluators for the relevant condition.

4. ICD-10 and coverage check — The recommendation is anchored to a documented, matching diagnosis code and checked against Medicare LCD/NCD coverage policy.

The same presentation routed two ways. The difference is rarely the panel ordered — it is whether anything was ruled out first.

What this catches that a straight-to-panel approach misses

Presentations where a reversible cause is documented but wasn't connected to the neuropathy symptoms in the differential
Cases where a hereditary pathway is genuinely appropriate, but the chart doesn't yet document the safety-gate workup a payer will expect to see
Patients whose earlier, non-genetic workup was incomplete rather than negative — a gap worth closing before, not instead of, genetic testing

Once safety gates clear, the presentation is matched to Tier-1 evaluators for the relevant condition.

Who this is for

Ordering clinicians who want confirmation that a genetic order is the right next step, not just an available one
Neurologists and genetic counselors managing patients with ambiguous or overlapping presentations
Molecular labs reducing denials tied to genetic orders placed before standard workup was documented

See how safety gates shape the recommendation before the panel does.

Request a demo